leisure time -WSS

leisure time

author：knowledge 2025-10-01 15:28:00 - browse：17438

Kuldeep Singh Rajput -- health tech coverage from STAT — Kuldeep Singh Rajput has left his role as CEO of Biofourmis. World Economic Forum

A month after conducting significant layoffs, Biofourmis is out a CEO: Kuldeep Singh Rajput, one of the company’s founders, has quietly stepped down from his role.

A Biofourmis spokesperson confirmed Rajput’s departure to STAT on Wednesday, and said that while the company hunts for a new CEO it will be helmed by a committee of executives overseen by new board member Ben Wanamaker, a partner at Biofourmis investor General Atlantic. The Boston-based company was valued at $1.3 billion following a $320 million Series D financing round which closed last summer and brought big names to Biofourmis: CVS Health was an investor, and Omar Ishrak, former CEO of Medtronic, and Sachin Jain, CEO of the SCAN Health Plan joined the board.

Founded in 2015, Biofourmis has been developing a dizzying array of tech-enabled care offerings, including home-based care services for hospitals, clinical trials support for biopharma companies, and a pipeline of software-based interventions for heart failure and other conditions.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Megan Rapinoe shares emotional post following US Women's World Cup exit

WSS

Megan Rapinoe shares emotional post following US Women's World Cup exit

The problems with dementia villages

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Readout: Friday, Oct. 20 biotech updates

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

knowledge

leisure time

explore

Drug repurposing or repositioning? The language matters

Roche drug slashes death risk in early

Malaria cases in Florida and Texas: Here’s what you need to know

Treatments for cramps don't cut it. Why aren't there better options?

How one medical school became remarkably diverse

Roivant's CEO is a star, but biotech's black hole persists

23andMe had bad news about my health. I wish a person had delivered it

Biden administration begins canceling student loan debt for 804,000 borrowers

Drug repurposing or repositioning? The language matters

Illumina slashes 2023 revenue projections yet again

focus

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Roche drug slashes death risk in early

Health AI: on the border between health care and tech

After Optum profits sink, UnitedHealth makes changes

How AI can help patients find reliable information about doctors

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

focus

leisure time

leisure time

hotspot